S Tritschler

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. Ledderose S, Beck V, Chaloupka M, Kretschmer A, Strittmatter F, Tritschler S. [Management of ureteral injuries]. Urologe A. 2019;58:197-206 pubmed publisher
    ..For minor injuries, the insertion of a ureteral splint is usually the treatment of choice. In the case of higher grade damage, operative reconstruction by one of several possible surgical procedures is indicated. ..
  2. Beck V, Schlenker B, Herlemann A, Apfelbeck M, Buchner A, Gratzke C, et al. The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade. World J Urol. 2018;: pubmed publisher
    ..These findings may be related to a reduced acceptance of PSA-based screening and the use of active surveillance as management strategy and have significant impact on daily patient care. ..
  3. Tritschler S, Lellig K, Roosen A, Horng A, Stief C. [Organ and function preservation in urethral cancer]. Urologe A. 2014;53:1310-5 pubmed publisher
    ..In case of locally advanced tumors or tumors of the proximal urethra, a radical urethrectomy with supravesical urinrary diversion is necessary. In some cases neoadjuvant (radio-)chemotherapy may be an option. ..
  4. Li M, Ballhausen H, Hegemann N, Ganswindt U, Manapov F, Tritschler S, et al. A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT. Radiat Oncol. 2015;10:82 pubmed publisher
    ..Further study of 3DUS for image guidance in a large patient cohort is warranted. ..
  5. Tritschler S, Erdelkamp R, Stief C, Hentrich M. [Neuroendocrine prostate cancer]. Pathologe. 2018;: pubmed publisher
    ..In patients with much higher serum PSA levels, chemotherapy with carboplatin plus docetaxel should be considered. ..
  6. Herlemann A, Buchner A, Kretschmer A, Apfelbeck M, Stief C, Gratzke C, et al. Postoperative upgrading of prostate cancer in men ?75 years: a propensity score-matched analysis. World J Urol. 2017;35:1517-1524 pubmed publisher
    ..The increased risk of upgrading should be taken into consideration when discussing optimal treatment for this specific cohort. ..
  7. Tritschler S, Erdelkamp R, Stief C, Hentrich M. [Neuroendocrine prostate cancer]. Urologe A. 2017;56:1475-1484 pubmed publisher
    ..In patients with much higher serum PSA levels, chemotherapy with carboplatin plus docetaxel should be considered. ..